The present invention refers to the field of biochemistry and in particular to technologies concerning the detection of nucleic acids.
Detection of specific oligonucleotide sequences has important applications in medical research, clinical diagnosis, food and drug industry, and environmental monitoring.
Most assays identify specific sequence through hybridization of an immobilized probe to the target analyte after the latter has been modified with a covalently linked label such as a fluorescent or radioactive tag. Oligonucleotide detection schemes that avoid analyte tagging, such as surface plasmon resonance, imaging ellipsometry, and sandwich assays using chemically functionalized gold nanoparticles, have also been invented. Gold nanoparticles covalently functionalized with DNA sequences to bind specific target DNA sequences for oligonucleotide sensing have also been used.
Present assays are dominated by chip-based methodologies that detect DNA sequences through hybridization of an immobilized probe to the target analyte that is labeled with fluorescent, radioactive and chemiluminescent molecular probes. Other biosensor approaches, such as surface plasmon resonance, imaging ellipsometry, quartz crystal microbalance etc, eliminate the use of biohazard labels but still require complex surface attachment chemistry for probe immobilization and expensive equipments for detection. In addition, the hybridization to sterically constrained probes on surface suffers from slow response and low efficiency. All these disadvantages (using complex labels, surface functionalization chemistry, low hybridization efficiency, and the use of expensive and bulky measurement instrumentation) render the chip-based methodologies less amendable for fast and robust DNA detection for point-of-care applications and for on-site applications.
Therefore, there is a need for a nucleic acid recognition assay that is fast and requires no modification of the probe or target nucleic acid.
In a first aspect the present invention is directed to a method of detecting presence or absence of a target nucleic acid, wherein the method comprises:
providing a nucleic acid probe with a substantially neutral net charge and contacting the nucleic acid probe with a sample which is suspected to comprise the target nucleic acid to result in a first mixture; wherein the nucleic acid probe is substantially complementary to the target nucleic acid;
contacting the first mixture with negatively charged metallic nanoparticles to result in a second mixture;
determining whether the target nucleic acid is comprised in the second mixture or not.
In a second aspect the present invention is directed to a method of detecting presence or absence of a target nucleic acid, wherein the method comprises:
incubate negatively charged metallic nanoparticles with a sample which is suspected to comprise the target nucleic acid to form a first mixture;
contacting the first mixture with a nucleic acid probe with a substantially neutral net charge to result in a second mixture; wherein the nucleic acid probe is substantially complementary to the target nucleic acid;
determining whether the target nucleic acid is comprised in the second mixture or not.
In a further aspect the present invention is directed to a kit for detecting presence or absence of a target nucleic acid in a sample; wherein the kit comprises:
at least one nucleic acid probe with a substantially neutral net charge;
at least one type of negatively charged metallic nanoparticles.
In still another aspect the present invention is direct to the use of at least one type of negatively charged metallic nanoparticle in a method of the present invention or in a kit of the present invention.
In still another aspect the present invention is direct to the use of at least one nucleic acid probe with a substantially neutral net charge in a method of the present invention or in a kit of the present invention.
The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings, in which:
The present invention is based on the fact that the absorption, such as the UV-vis absorption, of dispersed metallic nanoparticles (NPs) in a solution changes when the nanoparticles are aggregated. The aggregation degree is influenced by the exposure to different nucleic acids. This fact can be used to create a detection assay. For such a detection assay nucleic acids with a substantially neutral net charge are used as probe to detect the hybridization of negatively charged target nucleic acids, such as DNA and RNA. The nucleic acid probe with the substantially neutral net charge as such, a hybrid of a target nucleic acid with the nucleic acid probe formed by complementary binding of target nucleic acid with nucleic acid probe, and non hybridized mixtures of nucleic acid probe and target nucleic acid (due to no matching in the nucleic acid sequence and thus no complementary binding) exert different effects on the metallic nanoparticles behavior due to their different ability to interact with the metallic nanoparticles.
Thus, in a first aspect the present invention is directed to a method of detecting presence or absence of a target nucleic acid in a solution. This method does not require that any of the molecules involved in the method is attached to a solid phase. All components used can be dispersed in a liquid or aqueous solution. The method comprises:
providing a nucleic acid probe with a substantially neutral net charge and contacting the nucleic acid probe with a sample which is suspected to comprise the target nucleic acid to result in a first mixture; wherein the nucleic acid probe is substantially complementary to the target nucleic acid;
contacting the first mixture with negatively charged metallic particles to result in a second mixture;
determining whether the target nucleic acid is comprised in the second mixture or not.
In one embodiment the target nucleic acid is a label-free target nucleic acid or unlabeled target nucleic acid. With this method the presence and absence of a specific target nucleic acid sequence down to a single-base mutation in the nucleic acid can be determined rapidly by measuring for example the absorbance or change in particle size caused by aggregation in the particle solution. This method is fast and efficient since hybridization is completely separated from detection, thus eliminating sterical constrains of surface-bound probes or labeled probes which slow down hybridization and the entire detection process dramatically. This method is also easier to use because it does not require a modification of the nucleic acid probe or target nucleic acid (labeling with fluorescence or radioactive marker, coupling to enzymes, etc.) for detection.
The term “nucleic acid molecule” as used herein refers to any nucleic acid in any possible configuration, such as single stranded, double stranded or a combination thereof. Nucleic acids include for instance DNA molecules, RNA molecules, analogues of the DNA or RNA generated using nucleotide analogues or using nucleic acid chemistry, locked nucleic acid molecules (LNA), PNA molecules and tecto-RNA molecules (e.g. Liu, B., et al., J. Am. Chem. Soc. (2004) 126, 4076-4077). An LNA molecule has a modified RNA backbone with a methylene bridge between C4′ and O2′, which locks the furanose ring in a N-type configuration, providing the respective molecule with a higher duplex stability and nuclease resistance. Unlike a PNA molecule an LNA molecule has a charged backbone. DNA or RNA may be of genomic or synthetic origin and may be single or double stranded. Such nucleic acid can be e.g. mRNA, cRNA, synthetic RNA, genomic DNA, cDNA synthetic DNA, a copolymer of DNA and RNA, oligonucleotides, micro RNA having a length of between about 21 to 23 nucleotides etc. A respective nucleic acid may furthermore contain non-natural nucleotide analogues.
Many nucleotide analogues are known and can be present and/or used in the methods of the invention. A nucleotide analogue is a nucleotide containing a modification at for instance the base, sugar, or phosphate moieties. As an illustrative example, a substitution of 2′-OH residues of siRNA with 2′F, 2′O-Me or 2′H residues is known to improve the in vivo stability of the respective RNA. Modifications at the base moiety include natural and synthetic modifications of A, C, G, and T/U, different purine or pyrimidine bases, such as uracil-5-yl, hypoxanthin-9-yl, and 2-aminoadenin-9-yl, as well as non-purine or non-pyrimidine nucleotide bases. Other nucleotide analogues serve as universal bases. Universal bases include 3-nitropyrrole and 5-nitroindole. Universal bases are able to form a base pair with any other base. Base modifications often can be combined with for example a sugar modification, such as for instance 2′-O-methoxyethyl, e.g. to achieve unique properties such as increased duplex stability.
The “nucleic acid probe with a substantially neutral net charge” refers in general to a nucleic acid which comprises instead of the normal negatively charged ribose- or deoxyribose-phosphodiester backbone a backbone which is not charged (neutral). With ‘substantially neutral’ it is meant that the nucleic acid probe can include a nucleotide with a charged group, such as a negative group or a positive group as long as this does not influence the binding capability of the nucleic acid probe to the metallic particles or in other words as long as the positive or negative charges are not sufficient to balance the shielded negative charges of the metallic particles.
For example, a nucleic acid probe with a substantially neutral net charge could comprise glutamic acid and/or aspartic acid to introduce negative charges to PNA without affecting its ability to bind to the metallic nanoparticles in a more stable manner than nucleic acids, such as DNA or RNA. Also, a nucleic acid probe with a substantially neutral net charge modified with lysine, which has a positive charge, could also be used without affecting the functionality of the nucleic acid probe referred to herein. For example, a PNA used as nucleic acid probe and carrying a positive charge was shown to bind even more effectively to metallic nanoparticles, such as gold nanoparticles and such a modified nucleic acid probe can cause even more aggregation of the metallic nanoparticles. Thus the sensitivity using slightly positively charged nucleic acid probes, such as PNA can be higher.
In one embodiment, the nucleic acid probe with a substantially neutral net charge is not a single stranded DNA (ssDNA).
In one embodiment a PNA probe is used as nucleic acid probe with a substantially neutral net charge. It was found that for example PNA binds more effectively to the metallic nanoparticles than DNA thus making PNA a suitable tool for use in the method of the present invention.
A peptide nucleic acid (PNA) used in the present invention is a molecule which is similar for example to DNA or RNA in that it comprises nucleobases. However, instead of a negatively charged phosphodiester backbone to which the nucleobases are bound it comprises a pseudo-peptide backbone. In more detail, in a PNA the purine (A, G) and pyrimidine (C, T, U) bases are attached to the backbone through methylene carbonyl linkages. Unlike DNA, RNA, DNA analogs or RNA analogs, PNAs do not contain any (pentose) sugar moieties or phosphate groups.
By convention, PNAs are depicted like peptides, with the N-terminus at the first (left) position and the C-terminus at the right. Besides the obvious structural difference, PNA is set apart from DNA or RNA in that the backbone of PNA is acyclic, achiral and in case of the present invention substantially neutral. PNAs can bind to complementary nucleic acids in both antiparallel and parallel orientation. However, the antiparallel orientation is strongly preferred, and the parallel duplex has been shown to have a different structure. In an embodiment of the present invention PNA/nucleic acid duplexes refer to the antiparallel complex. The Watson Crick base pairing rules are strictly observed in hybrids of PNA and nucleic acids.
Thus, PNA is capable of hybridising at least complementary and substantially complementary nucleic acid strands, just as e.g. DNA or RNA, to which PNA is considered a structural mimic. Since a PNA molecule has a neutral backbone, hybridization with target nucleic acids is furthermore not affected by the interstrand negative charge electrostatic repulsions. The binding of PNA to DNA and RNA targets is accordingly stronger than the binding of DNA to DNA or RNA to RNA. PNA/DNA or PNA/RNA hybrids thus show a very stable duplex formation even at a relatively high temperature, and a very high binding affinity. Additionally, the absence of a repetitively charged backbone also prevents a PNA molecule from binding to proteins that normally have an affinity to polyanions. Hence, the use of PNA avoids a major source of non-specific interactions.
As mentioned, a PNA molecule is a synthetic nucleic acid analogue with a pseudopeptide backbone in which the phosphodiester backbone present in e.g. DNA or RNA is replaced by repetitive units of short aliphatic moieties with an amino end and a carboxylic end, forming an amide bond in the oligomer or polymer. To the short aliphatic moieties of the backbone, nucleobases, usually purine and pyrimidine bases, are attached via a side chain, generally a methyl carbonyl linker. In a PNA molecule any desired nucleobase, including purine and pyrimidine bases, may be used. Examples of suitable purine and pyrimidine bases include, but are not limited to, cytosine, 5-methylcytosine, guanine, adenine, thymine, uracil, 5,6-dihydrouracil, hypoxanthine, xanthine, ribothymine, 7-methylguanine or 7-isobutylguanine. A number of further suitable illustrative nucleobases that may also be termed “modified” nucleobases have recently been reviewed by Wojciechowski & Hudson (Current Topics in Medicinal Chemistry (2007) 7, 667-679). These include inter alia 4-(1,2,4-triazolypthymine, 5-alkynyluracil, 5-iodouracil, thiouracil, 5-(propargyl alcohol)uracil, iso-cytosine, pseudoisocytosine, 5-(ferrocenylpropargylcarboxamide)uracil, N6-alkyladenine, N7-xanthine, 3-nitropyrrole, 6-thioguanine, phenoxazine, 2-aminopurine or 2,6-diaminopurine.
The classical and most used PNA consists of repeating N-(2-aminoethyl)-glycine units linked by amide bonds. However, the backbone of this PNA lends itself to further chemical modifications. For example, the glycine units in the N-(2-aminoethyl)-glycine unit can be easily substituted either partly or completely by all naturally occurring amino acids. In one embodiment of the present invention it is preferred that the amino acids which are used to replace glycine also have a neutral net charge, such as alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, cysteine. Other modifications of the backbone of PNAs which are known in the art can also be used herein.
In one embodiment, the nucleic acid probe used in the method of the present invention has a length of between about 8 to 50 nucleosides or between about 10 to 30 nucleosides. In another embodiment the nucleic acid probe has a length of between about 8 to 25 nucleosides or between about 10 to 25 nucleosides. In examples referred to herein the nucleic acid probe has a length of 10, 13, 20 and 22 nucleosides.
The target nucleic acid can be any nucleic acid which can be comprised in a sample to be tested. This nucleic acid can be a naturally occurring nucleic acid or a modified nucleic acid comprising any of the nucleic acid modifications referred to above. In one embodiment, the target nucleic acid is DNA or RNA, such as micro RNA, or derivatives of such nucleic acids. The target nucleic acid can be a single stranded or double stranded nucleic acid. The target nucleic acid can but does not need to be labeled to be detectable with the method of the present invention. A “label” or “detectable label” is a moiety that can be sensed. Such labels can be, without limitation, fluorophores (e.g., fluorescein (FITC), phycoerythrin, rhodamine), chemical dyes, or compounds that are radioactive, chemoluminescent, magnetic, paramagnetic, promagnetic, quantum dots or enzymes that yield a product that may be colored upon reaction with a specific substrate, chemoluminescent, or magnetic. The signal generated by a label is generally detectable by any suitable means, including spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means.
The method of the present invention cannot only be used to detect the presence or absence of the target nucleic acid but also to quantify the amount of target nucleic acid present. Depending on the amount of target nucleic acid present in a sample compared to another sample in which the target nucleic acid is comprised in a different amount, the degree of metallic particle aggregation will vary. A change of the degree of metallic particle aggregation will change for example the absorbance of the solution or the size of the metallic particle aggregate. This difference can be correlated to different amounts of target nucleic acid present in the sample. To determine the exact amount of target nucleic acid present in the sample the results obtained from a sample can be compared with the results of a sample comprising a known amount of target nucleic acid. Methods to carry out such correlations are known in the art and include for example the generation of calibration curves obtained by measuring samples including a known amount of a target nucleic acid or different target nucleic acids.
In one embodiment, multiple target nucleic acids are measured in one sample by providing multiple nucleic acid probes which are specific for different target nucleic acids. In one embodiment two or three different target nucleic acids are measured in parallel in one sample. The resulting optical property of the metallic particle aggregates changes in case more than one target nucleic acid is present and thus allows determining whether only one target nucleic acid is present or more than one. In one embodiment, different metallic particles are used which have different optical properties and thus can result in different absorbance signals which can be easily differentiated by spectroscopic methods known in the art.
The degree of aggregation of the metallic nanoparticles referred to herein changes upon binding of a nucleic acid. The degree of aggregation depends on the kind of nucleic acid that binds. Aggregation changes for example the absorbance or the size caused by aggregation of multiple single nanoparticles. These changes can be measured using standard microscopic or spectroscopic methods.
In one embodiment, to enhance the measurability of these changes the metallic nanoparticles are plasmonic nanoparticles. Plasmonic nanoparticles refer to metallic nanoparticles whose surface Plasmon resonance frequency depends on the nanoparticle size, shape and composition. Light incident on plasmonic nanoparticles induces the conduction electrons in them to oscillate collectively with a certain resonant frequency. This resonant frequency changes in case the metallic nanoparticles aggregate and thus can be measured, e.g. with optical methods.
For example, a single 80-nm silver nanosphere scatters 445-nm blue light with a scattering cross-section of 3×10−2 μm2. The shape of the nanoparticle extinction and scattering spectra, and in particular the peak wavelength λmax depends on nanoparticle composition, size, shape, orientation and local dielectric environment.
Manufacture of such plasmonic nanoparticles is known in the art (see e.g. Grabar, K. C., Freeman, R. G., et al., 1995, Anal. Chem., vol. 67, pp. 735). Such nanoparticles can be obtained in any known shape. For example, in one embodiment the nanoparticles have a shape which is selected from the group consisting of a nanosphere, a nanocube, a nanorod, a nanotube, a nanostar, a nanocrescent, a nanoplate and mixtures thereof. With mixtures thereof it is meant that the nanoparticles used can include nanoparticles having not only a tubular shape but also nanoparticles having a plate like shape. In one embodiment, different nanoparticles with different shapes can be used in case more than one target nucleic acid is to be detected.
Although silver and gold are the most commonly used materials for plasmonic nanoparticles theoretically any metal, alloy or semiconductor with a large negative real dielectric constant and small imaginary dielectric constant can be used. In one embodiment the nanoparticles are alloys of noble metal particles or mixtures of materials referred to herein. Other materials, such as aluminium, potentially offer advantages in refractive index sensitivity, different surface chemistries, and resonances into the ultraviolet, where many organic molecules absorb light. Copper can also be used as possible metal for the metallic nanoparticles.
In one embodiment, the metallic nanoparticles each have a size in at least one dimension or at least 10 nm or 20 nm or in a range of between about 10 nm to about 900 nm or in a range of between about 10 to 50 nm. In another example the size of the nanoparticles is in range of between about 10 to 30 nm, or 20 to 30 nm.
To avoid that the metallic nanoparticles aggregate even without that any nucleic acid is present negatively charged metallic nanoparticles are used. In one embodiment the negatively charged metallic nanoparticles are metallic nanoparticles carrying a negative charge at nanoparticle surface. Binding of a nucleic acid changes the repulsion of the metallic nanoparticles and thus leads to an aggregation. As more of the negative charges of the metallic nanoparticle are shielded by a nucleic acid as higher the degree of aggregation of the metallic nanoparticles. For example, binding of the nucleic acid probe with the substantially neutral net charge alone (i.e. target nucleic acid not present) leads to a high degree of aggregation (see also
Metallic nanoparticles with a negative surface charge can be nanoparticles wherein the negative charge of the metallic nanoparticles is conferred by a carboxylic acid or sulfonic acid or carbolic acid or a mixture of the aforementioned acids which is immobilized at the surface of the metallic nanoparticles.
In one embodiment, the carboxylic acid can be, but is not limited to citric acid, lactic acid, acetic acid, formic acid, oxalic acid, uric acid, pyrenedodecanoic acid, mercaptosuccinic acid, aspartic acid, to name only a few. Methods to immobilize such acids at the surface of metallic nanoparticles are known in the art. For example, citrate-stabilized AuNPs were prepared by thermal reduction of HAuCl4 with sodium citrate (Grabar, K. C., Freeman, R. G., et al., 1995, supra). In brief, 500 mL of 1 mM HAuAl4 was brought to a rolling boil with vigorous stirring. After that 50 mL of 38.8 mM sodium citrate was rapidly added, resulting in burgundy color. Boiling was continued for 10 min; the heating mantle was then removed, and stirring was continued for additional 15 min. Maya, L., et al. (2002, Langmuir, vol. 18, pp. 2392) discloses a method for immobilizing mercaptosuccinic acid at the surface of metallic nanoparticles. Tan, Y. N., et al., (2008, J. Phys. Chem. C, vol. 112, no. 14, pp. 5463) discloses a method for immobilizing aspartic acid at the surface of metallic nanoparticles. It was also found that the lower the surface charge density the higher for example the DNA or RNA detection sensitivity.
The nucleic acid probe can be fully complementary to the target nucleic acid or only partly complementary to the target nucleic acid. In other words, the nucleic acid probe can have a sequence comprising one or more non-complementary nucleotides. This allows detecting the presence and absence of a target nucleic acid comprising one or more mutations in its sequence compared to the sequence of the nucleic acid probe. As demonstrated herein and illustrated in
To increase the sensitivity for the method of the present invention, for example to differentiate between target nucleic acids which are fully complementary to the sequence of the nucleic acid probe and which comprise one or more mutations in their sequence, it is possible to add a compound comprising cations, such as monovalent or divalent cations or mixtures thereof. Cations are used to screen the negative charges at the surface of the metallic nanoparticles and thus to induce more intensive aggregation.
Suitable salts that can be used herein include any inorganic salt. Any salt could increase the ionic strength of the mixture, screening the charge repulsion between the particles and between particles and the nucleic acid strand of the target nucleic acid. Examples, of inorganic salts include, but are not limited to NaCl, KCl, CaCl2, BaCl2, MgCl2, NaBr, KBr, NaI, KBr, NaNO3, KNO3, Mg(NO3)2, Ca(NO3)2, Na2SO4, K2SO4, NaClO4, NH4Cl, NH4NO3, (NH4)2SO4, CH3COONa, CH3COONH4, to name only a few. The concentration of the cations in the solution can be in the range of between about 0.01 M to about 1 M, or between about 0.01 M to about 0.5 M, or between about 0.01 M to about 0.1 M.
To increase the sensitivity of the method referred to herein it is also possible to increase the temperature, for example, to increase the sensitivity for detecting single base mismatches. For example, it was found that a single base mismatch lowers the melting temperature (the stability) for about 13° C. It would therefore be possible to set the temperature in between the fully match and mismatch so as to enhance the sensitivity or selectivity for single base mismatch.
As previously mentioned, determining the presence, the absence or the amount of the target nucleic acid can be achieved by measuring the optical properties of the metallic nanoparticles or by measuring the size of the metallic nanoparticle aggregates formed.
The optical properties such as the absorbance can be determined with methods and devices known in the art, such as with a spectrophotometer. If the change of the optical properties is visible in the light wave range visible to humans it is also possible to determine the differences with the naked eye. The size of the nanoparticle aggregates which form upon binding of a nucleic acid can be determined with transmission electron microscopy (TEM), or light scattering techniques or a coulter counter for small particles.
The components used in the method of the present invention are preferably comprised in a solution, such as an aqueous solution. In one embodiment, the pH in the solution in which the method of the present invention is carried out is neutral (i.e. about pH 7). A neutral pH is used to avoid dehybridization of the hybrid complexes formed between nucleic acid probe and target nucleic acid. The temperature in the solution is preferably lower than the melting temperature of a hybrid complex formed between the nucleic acid probe and the target nucleic acid. All kinds of buffers can be used to conduct the method of the present invention therein, such as a phosphate buffered saline (PBS) or tris(hydroxymethyl)aminomethane (TRIS) buffer, to name only a few. In one embodiment, a buffer concentration in a range of between about 0.001 mM to about 500 mM can be used in the method referred to herein.
In a second aspect the present invention refers to a method of detecting presence or absence of a target nucleic acid. This method comprises:
incubate negatively charged metallic nanoparticles with a sample which is suspected to comprise the target nucleic acid to form a first mixture;
contacting the first mixture with a nucleic acid probe with a substantially neutral net charge to result in a second mixture; wherein the nucleic acid probe is substantially complementary to the target nucleic acid;
determining whether the target nucleic acid is comprised in the second mixture or not.
In a further aspect, the present invention refers to a kit for detecting presence or absence or for determining the amount of one or more target nucleic acid(s) in a sample. The kit can comprise at least one nucleic acid probe with a substantially neutral net charge described herein and/or at least one type of negatively charged metallic nanoparticle described herein.
In a further aspect the present invention is directed to at least one type of negatively charged metallic nanoparticle which can be used in a method or the kit of the present invention. Furthermore, the present invention is also directed to at least one nucleic acid probe with a substantially neutral net charge as described herein which can be used in a kit or a method of the present invention.
The inventions illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising”, “including”, “containing”, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.
The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
Other embodiments are within the following claims and non-limiting examples. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
Reagents
HAuCl4.3H2O (99.99%) and AgNO3 (99.9%) were obtained from Alfa Aesar (MA). Trisodium citrate dihydrate (99.9%) was obtained from Aldrich and NaBH4 from Fluka. Concentrated HCl and HNO3 were all analytical grade and used without further purification. Mixed-base PNA oligomers of 10-, 13-, 20-, and 22-mer (denoted as PNA10, PNA13, PNA20, and PNA22) with no modification at C- and N-terminals, were synthesized by the Eurogentec S.A. Leige (Belgium). Target DNA of fully complementary (DNAcomp), noncomplementary (DNAnc), and single-basemismatch sequence (DNAm1) were from Proligo-Sigma (for PNA and DNA sequences, see Table 1).
Colloidal Preparation
Citrate-stabilized AuNPs were prepared by thermal reduction of HAuCl4 with sodium citrate (Grabar, K. C., Freeman, R. G., et al., 1995, Anal. Chem., vol. 67, pp. 735). Citrate-stabilized AgNPs were synthesized by the reduction of silver nitrate using sodium borohydride. Spherical AuNPs of 13.2±1.1 nm and AgNPs of 16.1±0.6 nm were observed under TEM. The concentrations of the AuNPs and AgNPs were 7.3 and 0.39 nM, respectively, calculated according to Beer's law, using the extinction coefficient of 2.7×108 M−1 cm−1 for 13 nm AuNPs30 and 9.4×109 M−1 cm−1 for 16 nm AgNPs.
Characterization
Ninety-six-well microplates were used as reaction carrier. UV-vis absorption characterization was performed using a TECAN infinite M200 (Tecan Trading AG, Switzerland). The reproducibility of the UV-vis absorption spectrum measurement (at room temperature) was evaluated through multiple scans of a given AuNPs (and AgNPs) solution aliquot in different wells. The variation of the absorbance measurement at representative wavelengths is about 1% for AuNPs and within 2% for Ag—NPs (
Assay Procedure
To test the coagulating property of PNA, aliquots of stock PNA probes (100 μM) were added to 150 μL of AuNPs (or AgNPs) solution. After 10 min incubation at room temperature, the color of the solutions was recorded using a camera and the absorption spectra were recorded in a wavelength range of 400-800 nm for AuNPs and 300-800 nm for AgNPs. To measure the ability of PNA-DNA complex and dsDNA to protect AuNPs (or AgNPs) and to detect the sequence specific hybridization, the PNA (or DNA) probe and DNA target of equal amount (40 μM) were annealed in 20 mM phosphate buffer (pH 7.2, containing 100 mM NaCl, and 0.1 mM EDTA), prior to addition to nanoparticle solutions (150 μL) (final DNA concentration 1 μM). When necessary, NaCl (final concentration 0.1-0.4 M) was added to accelerate particle aggregation. To test PNA hybridization with DNA inside AuNPs solution, DNA was first mixed with AuNPs (final DNA concentration 1 μM, final buffer concentration is 1 mM PBS). After 10 min incubation, PNA (final concentration 1 μM) was added.
PNA Binds More Strongly to AuNPs than its ssDNA Counterpart
Reproducibility of UV-vis Spectrum Measurement for AuNPs and AgNPs
The reproducibility of the UV-vis spectrum measurement by performing multiple scans to a AuNPs solution (or a AgNPs solution) aliquot in eight different wells was evaluated. The obtained spectra from the eight wells overlapped extremely well (
Surface Plasmon Resonance (SPR) Detection of DNA Hybridization with Immobilized PNA13 Probe
A biotinylated PNA13 is immobilized on SPR gold disk using streptavidin-biotin interaction. The hybridization of fully complementary and single-base-mismatched target DNA (DNAcomp and DNAm1) were monitored in real-time (
PNA-Induced AuNPs Aggregation
A study of PNA-induced AuNPs aggregation with the involvement of four mixed-base PNA oligomers of different chain length (10-, 13-, 20-, and 22-mer) and base composition was conducted, aiming to extract PNA-AuNPs binding characteristics in terms of concentration, sequence, and chain length dependence.
Parts A and B of
To better understand the mechanism of PNA induced AuNPs aggregation, the surface charge of AuNPs before and after PNA coating (PNA13 was used as an example) was measured. It was found that PNA13-coated AuNPs has a similar charge density (ζ-potential −20.11±3.6 mV) as compared to the uncoated AuNPs (ζ-potential −21.04±2.6 mV). This suggests that the PNA coating only shields the citrate ions (no displacement occurs). This concurs with previous Raman spectroscopy result for single-stranded oligonucleotides (ssDNA), showing that coating of ssDNA on AuNPs did not displace citrate ions. However, the inability of charge neutral PNA oligomers to displace citrate ions from gold surface appears to conflict with previous studies for other charge neutral substances, e.g., adenosine, nucleobases, and nucleosides.
Coating of these small molecules has been proven to be able to displace weakly bound citrate ions from AuNPs. It might be the steric hindrance arising from the polymer structure of the PNA oligomers makes the binding not strong enough to displace the citrate ions. Using DNA as an example, it was previously shown that ssDNA oligonucleotides bind less effectively to AuNPs than mononucleosides due to larger molecular size.
PNA Binds More Strongly to AuNPs than its ssDNA Counterpart
ssDNA is known to be able to adsorb on AuNPs and to stabilize colloidal suspensions in high salt concentration. However, in the presence of PNA, it was found that ssDNA's stabilization effect is abolished.
Stabilization Effect of PNA-DNA Complex
Apart from the fact that non-complementary DNA (denoted as DNAnc) has little interference to PNA-induced AuNPs aggregation, further experiments with complementary DNAcomp show that the presence of a small amount of DNAcomp can disrupt the particle aggregation significantly.
Apparently, the depletion of particle aggregation in the presence of DNAcomp is due to the reduction of free PNA upon formation of the PNA-DNA complex. The observation that particle aggregation is abolished when half of the PNA (at DNA/PNA ratio of 0.5) being consumed is evidence that the as-formed PNA-DNA complex prevents the remaining PNA (100 nM in this case) from aggregating the particles (PNA22 at 100 nM is sufficient to induce detectable aggregation in the absence of other species,
To further understand the binding property of PNA-DNA complex to AuNPs and to compare its protection of AuNPs relative to ssDNA and dsDNA, PNA13 and PNA20 and their corresponding complementary DNA of equal amount were annealed to form PNA-DNA complexes. The incubation solutions were then mixed with AuNPs. The stability of the colloidal solutions before and after addition of salt was recorded (
The discovery that despite the presence of double-helix geometry PNA-DNA duplexes can effectively protect AuNPs against salt induced aggregation, better than dsDNA and even ssDNA, is an interesting phenomenon. This phenomenon was rationalized from both the electrostatic and steric stands. First of all, a PNA-DNA duplex carries only half of the negative charges relative to its dsDNA counterpart. Under the low ionic strength conditions used in this experiment (<3 mM NaCl), the effective charge of PNA-DNA complex would be noticeably lower than that of dsDNA. This would enable the PNA-DNA complex to adsorb more effectively than dsDNA onto citrate ion-coated AuNPs, due to depleted charge repulsion. Second, the nitrogen-/oxygen-containing peptide backbone of the PNA strand can interact with gold, leading to a higher affinity than dsDNA. In a comparison between PNA-DNA complex and ssDNA, both having similar charge density but entirely different structure properties (insulated or exposed bases), it is not possible to speculate which one binds more effectively to gold with a higher affinity without characterizations using other techniques. But the stronger protection of PNA-DNA than ssDNA could be largely or at least partially attributable to the larger molecular size and the structure rigidity of PNA-DNA complex that introduces more steric protection than ssDNA. This interpretation is indirectly supported by the fact that the stability difference between PNA-DNA complex- and ssDNA-protected AuNPs is larger for the 20-mer samples than the 13-mer samples (more obvious UV-vis spectra difference in
The hypothesis that steric effect, rather than charge effect, is attributable for the better stability of PNA-DNA complex-protected AuNPs than ssDNA protected ones has been further supported by ζ-potential measurement (using the 13-mer sample as example). In 0.15 M NaCl, the ζ-potentials of AuNPs coated with PNA-DNA, ssDNA, and dsDNA are −31.2±8.2, −30.7±6.7, and −10.4±7.3 mV, respectively. The charge density of the PNA-DNA complex- and ssDNA protected AuNPs are similar, meaning that electrostatic repulsion is similar. Thus, the observed differential stability should be a result of differential steric effect. For the dsDNA-protected particles, the high ζ-potential value, indicating of reduced surface charge and reduced electrostatic repulsion, explains why aggregation occurs easily.
Thus, it was demonstrated that (1) mixed-base PNA oligomers can induce immediate particle aggregation, (2) PNA oligomer have a higher affinity to NPs than its ssDNA counterpart, (3) PNA-DNA complex, although having a stable double helix structure similar to dsDNA, can effectively protect NPs from salt induced aggregation, and (4) the ability of different nucleic acids to protect AuNPs against salt-induced aggregation is in the order PNA-DNA complex>ssDNA>dsDNA.
Nucleic Acids' Binding Characteristics to AgNPs
AgNPs have a higher extinction coefficient relative to AuNPs of the same size. It is therefore believed that AgNPs would have a higher sensitivity for use in colorimetric assays. Therefore, experiments were conducted with citrate ion protected AgNPs to extend the understanding of nucleic acid-AgNPs interactions and to address the sensitivity merit of this material for this particular application.
With these observations, we confirm that nucleic acids' binding characteristics and their stabilization effects are identical for AuNPs and AgNPs. The well-known characteristic that ssDNA, but not dsDNA, can protect AuNPs against salt induced aggregation is, for the first time, proven true for AgNPs. With this experiment it was also found that AgNPs are more sensitive in response to small difference in stabilization effect. The previous finding that PNA-DNA complex can better protect nanoparticles against salt-induced aggregation than ssDNA is further confirmed with Ag—NPs, via both the color change and UV-vis spectrum shift, whereas with AuNPs, only a slight spectrum shift is accountable for this characteristic (
Detection of Pre-Annealed PNA-DNA Complex with Single-Base-Mismatch Sensitivity Using AuNPs and AgNPs
Successful hybridization of PNA with its complementary DNAcomp can abolish PNA-induced particle aggregation. In the case where target DNA contains a single-base-mismatch (DNAm1), the less effective hybridization (or higher tendency of dehybridization) would cause some PNA to remain free in solution. It was thus anticipate that the unhybridized PNA would aggregate the particles, detectable by typical spectrum shifts.
Detection of PNA Hybridization with DNA in Pre-Incubated DNA/AuNPs Mixtures
According to the characteristic that PNA has a stronger affinity to AuNPs than ssDNA, an alternative approach was developed to detect a specific DNA through PNA-DNA hybridization in a DNA/AuNPs mixture but not through post addition of pre-annealed PNA-DNA complex. This approach is designed on the basis of the indication that PNA is able to strip DNA from the AuNPs surface and further hybridize to the DNA if the sequences are complementary.
In the following one-component assays and two-component assays are described for detecting nucleic acids. Depending on whether the AuNPs and AgNPs are used separately (Examples I to IV) or used in mixture (Example V), one-component assays and two-component assays have been used. Color change relies on either the change of nanoparticles' intrinsic stability (Examples I, IV, V) or the change of their stability against salt (Examples II, III-V).
As described above, neutrally charged PNA and negatively charged DNA (or PNA-DNA hybrids) exert different effects on AuNPs' stability and aggregation behavior.
When a PNA-DNA hybrid solution (equal amount of PNA and its complementary DNA were annealed to form hybrids in 10 mM phosphate buffer pH 7.2, 100 mM NaCl, and 0.1 mM EDTA) was added, the AuNPs solution remained stable and no aggregation took place. Color of the solution remained red (C). This is because capping of AuNPs with PNA-DNA complex retains sufficient negative charges (from the phosphate backbone of the DNA strands) on the particle surface, even though citrate anions are shadowed in the process.
When an irrelevant DNA was mixed with PNA probe (no formation of PNA-DNA complex due to non-match in sequence), certain extent of aggregation in the solution takes place, and color changes to purple (D), showing that the un-hybridized PNA probe binds dominantly to the particles, resulting in aggregation due to obscurity of the negative charges.
From the corresponding UV-vis spectra, it can be seen that there is a red shift of surface plasmon (SP) peak (λmax) from 520 nm for the well dispersed solution A and C to a longer wavelength of 600 nm for aggregated B and D. The spectra shift leads to an increase of absorbance at 600 nm and a decrease at 520 nm. The A600/A520 absorbance ratio value can be used as a quantitative measure of the aggregation extent. For solution C containing specific DNA hybridized to the PNA, the A600/A520 ratio is 0.26, whereas for solution D with a nonspecific DNA, the A600/A520 ratio is 0.76. Hence, increase of A600/A520 ratio between the two systems is 192%.
To determine the DNA detection sensitivity of the current colorimetric assay, different amount of target DNA (0-200 nM) was added to PNA probe (200 nM) solution for hybridization. A detection limit of <10 nM was obtained for the 13 mer DNA. The nanomolar sensitivity is comparable with results from other label free assays such as Surface Plasmon Resonance (SPR).
As discussed above, electrostatic repulsion between anions, such as citrate anions is essential to protect nanoparticles from aggregation. When this electrostatic repulsion is screened by salt (e.g. sodium chloride, NaCl), the nanoparticles tend to aggregate. NaCl is added into each solution from
For bare AuNPs without addition of nucleic acids (A), 0.1 M NaCl caused the particles to precipitate from the solution and the solution became colorless (no UV-vis absorption). In the presence of PNA (B) and PNA/DNA mixture (D), addition of NaCl led to further aggregation shown by the blue color and the further shift of UV-vis curves to longer wavelengths. On the other hand, in the presence of PNA-DNA hybrid (C), the particles remain well dispersed under 0.1 m NaCl as shown by the red color and the SP peak at 520 nm. Thus, test of AuNPs' stability against salt further affirms that presence of a specific target DNA which forms PNA-DNA hybrid can protect AuNPs from salt induced aggregation. To quantify the aggregation extent, the A600/A520 ratio was calculated for solution C (containing specific DNA hybridized with the PNA) and solution D (containing a non-specific DNA). The value was 0.32 and 1.069 respectively. The increase of A600/A520 ratio between the two systems is 243%, being slightly higher than that (192%) using intrinsic stability of nanoparticles alone.
Use of PNA as probe for colorimetric detection of DNA is more sensitive than that used in prior-art, which uses differential electrostatic interaction of single-stranded DNA (ssDNA) and double strand (dsDNA) with AuNP as colorimetric sensing principle.
Detection of single-base-mismatch in DNA is important for diagnosis of generic disease. The detection method of the present invention can also be used for this purpose through use of AuNP's stability against salt, as shown in the scheme in
PNA-DNA duplexes of fully complementary sequence and single-base-mismatch sequence have undistinguishable effect on AuNPs' intrinsic stability. Discrimination relies on a high stringent condition, with for example, an additional of NaCl (
It is believed that due to the presence of the mismatched base, the PNA-DNA hybridization efficiency is reduced, leaving some PNA unhybridized. The free PNA in the solution would bind in competition to AuNPs with negatively charged PNA-DNA hybrids and the ssDNA, and to deplete the stability of the nanoparticles, causing certain degree of aggregation. To quantify the particle aggregation in the presence of SBM target, the A600/A520 was calculated for both the complementary (0.44) and mismatch DNA (0.29). The value increases by 51.6%.
The same characteristic was obtained for a longer sequence of 22 mer. Detection of single-base-mismatch in a longer sequence (22 mer in this case) is more difficult than in a shorter sequence (13 mer sequence). To quantify particle aggregation in the presence of SBM for the 22mer target, the A600/A520 was calculated for both the complementary (0.43) and mismatch DNA (0.36). The value increases by 17.6%, being smaller than that (51.6%) for the mismatch detection in the 13 mer sequence. Successful detection of single-base-mismatch in the 22 mer sequence at room temperature is of significance. Other solid-liquid phase biosensor methods (SPR and electrochemical methods) can not detect single-base-mismatch in this sequence at room temperature without attempts to increase the hybridization stringency, such as using high temperature.
Silver nanoparticles (AgNPs) have also been used for a colorimetric assay. Citrate anion coated AgNPs solution is well dispersed, showing a yellow color (the SP peak is around 400 nm). Addition of a 22 mer PNA caused the AgNPs to aggregate, showing color and UV-vis spectrum changes (
Single-base-mismatch detection using AgNP's stability against salt is also demonstrated (
When AuNPs and AgNPs are used in mixture, a two-color-change assay is used.
The discrimination between fully complementary DNA and SBM DNA is detected by the two-color-change method at 0.2 M NaCl (0.1 M NaCl was found less suitable to differentiate,
This application claims the benefit of priority of U.S. provisional application No. 61/152,372, filed Feb. 13, 2009, the contents of it being hereby incorporated by reference in its entirety for all purposes.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/SG10/00047 | 2/10/2010 | WO | 00 | 11/17/2011 |
Number | Date | Country | |
---|---|---|---|
61152372 | Feb 2009 | US |